삼중음성유방암(TNBC) : 시장 인사이트, 역학 및 예측(2036년)

Triple Negative Breast Cancer (TNBC) Insights and Trends

• According to DelveInsight's analysis, TNBC market size was nearly USD 5 billion in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• According to DelveInsight's estimates, the total incident cases of breast cancer in the 7MM are nearly 700,000 in 2025 and cases are expected to rise due to to factors such as lifestyle changes, obesity, delayed childbirth, alcohol consumption, environmental exposures, and enhanced detection through screening programs.
• Recent advancements have introduced immunotherapy and targeted therapies, transforming the treatment landscape. Pembrolizumab (KEYTRUDA), an immune checkpoint inhibitor targeting PD-1, is now a standard treatment for early-stage TNBC, with chemotherapy as neoadjuvant therapy, followed by adjuvant monotherapy after surgery. For patients with BRCA mutations, targeted therapies like PARP inhibitors effectively exploit cancer cells' impaired DNA repair mechanisms. Olaparib (LYNPARZA) and Talazoparib (TALZENNA) are the leading PARP inhibitors, used primarily after 1L therapies or when immunotherapy is unsuitable. They have shown significant efficacy in prolonging PFS in BRCA-mutated TNBC.
• Emerging TNBC pipeline therapies, including DATROWAY (+- IMFINZI) in the first line and Tilarginine in later lines among others, highlight a shift toward mechanism-driven, combination strategies aimed at overcoming resistance and improving survival outcomes.
• Most breast cancers are diagnosed before a patient shows symptoms through routine breast cancer screening, such as mammography; however, TNBC mostly occurs in younger women before reaching the age for routine screening. So, its diagnosis mostly relies on patients noticing their symptoms, which often gets ignored, leading to delayed diagnosis. Also, being an aggressive subtype of breast cancer, it develops and progresses quickly. Hence, this delay in diagnosis often worsens patient prognosis, as most patient's cancer often develops significantly till they are diagnosed.

TNBC Market size and forecast

• 2025 TNBC Market Size in the 7MM: ~USD 5 billion
• TNBC Growth Rate (2026-2036): 13.3% CAGR (Compound Annual Growth Rate)

DelveInsight's 'Triple Negative Breast Cancer (TNBC)- Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of TNBC, historical and forecasted epidemiology, as well as the TNBC market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The TNBC market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, TNBC patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across the 7MM regions. The report highlights key unmet medical needs in TNBC and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Geography Covered:

North America: The United States

Europe: Germany, France, Italy, Spain and the United Kingdom

Asia-Pacific: Japan

Triple Negative Breast Cancer (TNBC) - Understanding and Treatment Algorithm

Triple Negative Breast Cancer (TNBC) Overview and Diagnosis

Breast cancer is a disease that is both genetically and clinically diverse, with various subtypes. The categorization of these subtypes has changed over time. The most commonly used and widely recognized classification system is based on immune histochemical analysis, which looks at the expression of hormone receptors such as Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2). The distinctive immune microenvironment of TNBC, which features elevated levels of vascular endothelial growth factors, Tumor-infiltrating Lymphocytes (TILs), Tumor-associated Macrophages (TAMs), and other molecules that support tumor cell growth and migration, plays a dual role in the development, progression, and spread of TNBC.

Common imaging methods for diagnosing TNBC include mammography, ultrasound, and MRI. Common biopsy techniques used for diagnosis include core biopsy, fine needle aspiration, stereotactic biopsy, and surgical biopsy.

Current TNBC Treatment Landscape

The current treatment landscape for TNBC is challenging due to the lack of hormone receptors (estrogen and progesterone) and minimal HER2 protein expression, which makes hormonal and HER2-targeted therapies ineffective. Consequently, chemotherapy remains the cornerstone of TNBC treatment across all stages.

In early-stage TNBC, neoadjuvant chemotherapy is often used to reduce tumor size and assess treatment response. This approach can also improve surgical outcomes by enabling breast-conserving surgery. Depending on residual disease after surgery, adjuvant chemotherapy may be recommended to decrease the risk of recurrence. Radiation therapy is also considered, especially when lymph nodes are involved, or breast-conserving surgery is performed.

As adjuvant therapy for TNBC, various chemotherapy regimens are employed to reduce recurrence risk and eliminate residual cancer cells. Common combinations include cyclophosphamide, doxorubicin, and paclitaxel, as well as cyclophosphamide with doxorubicin or docetaxel. Paclitaxel is also used as a standalone agent, while capecitabine is often administered for residual disease. Additionally, cyclophosphamide, fluorouracil, and methotrexate are utilized in select adjuvant treatment protocols.

Triple Negative Breast Cancer (TNBC) Unmet Needs

The section "unmet needs of TNBC" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Diagnostic delay leading to worsening of patient prognosis

2. Deeper understanding of the heterogeneity of the disease

3. High risk of recurrence and metastasis.

4. Lack of reliable biomarkers

5. Need for Novel therapies

Triple Negative Breast Cancer (TNBC) Epidemiology

Key Findings from TNBC Epidemiological Analysis and Forecast

• In 2025, the total number of incident TNBC cases in the 7MM were recorded at approximately 100,000, and this figure is projected to rise by 2036.
• In 2025, the US had the highest number of incident TNBC cases among the 7MM, accounting for nearly 42% of the total cases. The highest number of cases was recorded in individuals under 45 years of age, around 16,000 cases in 2025.
• In the UK, Stage II TNBC had the highest number of cases in 2025, with nearly 4,000 cases.
• In Japan, BRCA1-mutated TNBC had the highest number of cases among gene mutation-specific TNBC cases in 2025, nearing 1,000 cases.

Triple Negative Breast Cancer (TNBC) Drug Analysis & Competitive Landscape

The TNBC drug chapter provides a detailed, market-focused review of the emerging pipeline across Phase I-II clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the TNBC treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the TNBC therapeutics market.

Approved Therapies for TNBC

Pembrolizumab (KEYTRUDA): Merck

Pembrolizumab (KEYTRUDA) is an immunotherapy that enhances the body's ability to recognize and attack cancer cells. As a humanized monoclonal antibody, it blocks the interaction between the PD-1 receptor and its ligands, Programmed Death-ligand 1 and 2 (PD-L1) and (PD-L2), thereby activating T lymphocytes, which can affect both tumor and healthy cells. In TNBC, KEYTRUDA has been studied in combination with chemotherapy to improve treatment outcomes.

TNBC Marketed/Approved Therapies

Drug/Therapy Company Indication Molecule Type MoA RoA Marketed Region

Pembrolizumab

(KEYTRUDA) Merck TNBC Monoclonal antibody PD-1 inhibitor IV infusion US: 2020 and 2021,

EU: 2021 and 2022,

JP: 2021 and 2022

Sactizumab govitecan-hziy

(TRODELVY) Gilead Sciences TNBC Monoclonal antibody DNA topoisomerase I inhibitor IV infusion US: 2021,

EU: 2021,

JP: 2024

• In May 2024, Merck reported that its Phase III KEYNOTE-522 trial successfully met the overall survival endpoint in patients with high-risk early-stage TNBC.

Triple Negative Breast Cancer (TNBC) Pipeline Analysis

DATROWAY (Datopotamab Deruxtecan): AstraZeneca/Daiichi Sankyo

Datopotamab Deruxtecan (Dato-DXd) is an investigational antibody-drug conjugate (ADC) designed to selectively target cancer cells and deliver a potent chemotherapy payload. It is being developed as a precision medicine for the treatment of TNBC and is currently under evaluation across various TNBC subtypes in multiple clinical trials. Dato-DXd, also known as DATROWAY, is being studied both as a monotherapy and in combination with IMFINZI (durvalumab). This combination is being explored in the neoadjuvant and adjuvant settings for TNBC, as well as for PD-L1-positive patients with locally recurrent inoperable or metastatic TNBC, aiming to improve treatment outcomes for high-risk patients.

• In October 2025, Datroway demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic TNBC for whom immunotherapy was not an option in TROPION-Breast0.

TNBC Key Players, Market Leaders and Emerging Companies

• Merck
• Gilead Sciences
• Pfizer
• AstraZeneca/ Merck
• Hoffmann-La Roche

TNBC Drug Updates

• In February 2026, datroway was granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy.
• In January 2024, DSMB positively responded to the first interim analysis of the Phase III clinical trials of Adagloxad Simolenin (OBI-822)/OBI-821 active immunity vaccine for TNBC and suggested the company to continue the trials.

Triple Negative Breast Cancer (TNBC) Market Outlook

Pembrolizumab, olaparib, talazoparib, sacituzumab govitecan, and atezolizumab-demonstrate the evolving TNBC treatment paradigm. The focus has shifted from chemotherapy alone to a more personalized approach integrating immunotherapy and targeted therapies, significantly improving patient outcomes. However, the aggressive nature of TNBC and its poor prognosis ongoing research and clinical trials to enhance therapeutic options and survival rates. Prior to these recent developments, taxane-based chemotherapies have remained the standard of care for metastatic disease, specifically in 1L treatment. Platinum-based chemotherapies are also used at times in the 1L treatment setting. Still, their usage is highly debated among physicians, as they tend to have very severe adverse effects and do not have that good of treatment outcome (PFS) either.

• In 2025, the TNBC market across the 7MM was approximately USD 5 billion. The US accounted for about 70% of total revenues, followed by EU4 and the UK.
• The market size for TNBC in Japan was valued at approximately USD 200 million in 2025. It is expected that the market will show growth, mainly attributed to the increasing incident cases and the launch of upcoming therapy during the forecast period.
• Spain accounted for the least market size among the 7MM countries, which was nearly USD 100 million in 2025.

Drug Class/Insights into Leading Emerging Therapies in TNBC (2022-2036 Forecast)

• Monoclonal antibody: Monoclonal antibodies are increasingly central to the treatment landscape of TNBC, driven by their targeted and immune-modulating mechanisms. Immune checkpoint inhibitors such as KEYTRUDA and TECENTRIQ have demonstrated meaningful benefit, particularly in PD-L1-positive populations, by enhancing anti-tumor immune responses. In parallel, antibody-drug conjugates (ADCs) like TRODELVY and others are redefining outcomes by delivering potent cytotoxic agents directly to tumor cells, improving efficacy while minimizing systemic exposure. Ongoing development of novel monoclonal antibodies and next-generation ADCs, including DATROWAY, continues to expand therapeutic possibilities, with a strong focus on combination strategies.

Triple Negative Breast Cancer (TNBC) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the TNBC drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

AstraZeneca/Daiichi Sankyo is leading in the TNBC pipeline with multiple therapies targeting different stages and lines of treatment. Their key Phase III candidate, Datopotamab deruxtecan (DATROWAY) combined with Durvalumab (IMFINZI), is under investigation for 1L therapy, with data expected after 2026. This includes the TROPION-Breast04 trial for neoadjuvant/adjuvant TNBC and TROPION-Breast05 for PD-L1-positive metastatic TNBC. Another trial, TROPION-Breast03, evaluates Datroway with or without IMFINZI for adjuvant residual disease in TNBC. These trials explore a precision medicine approach, focusing on TROP-2 ADC combined with PD-L1 immunotherapy.

It is expected to be launched in the EU4 and UK market by 2028. The therapy is anticipated to experience Medium-fast market uptake and reach peak sales within 6 years of its introduction. It offers a promising new treatment option for patients with this aggressive form of cancer.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of therapies in Triple Negative Breast Cancer (TNBC)

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Triple Negative Breast Cancer (TNBC) therapies Price Scenario & Trends

Pricing and analogue assessment of TNBC therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of TNBC Approved Drugs

Several drugs have been approved for treating TNBC, each offering different mechanisms of action. In the US, pembrolizumab (KEYTRUDA) by Merck is approved for two TNBC indications: as neoadjuvant treatment with chemotherapy for high-risk early-stage TNBC, continued as adjuvant monotherapy post-surgery and in combination with chemotherapy for locally recurrent or metastatic TNBC with PD-L1 expression. It is the first immunotherapy to demonstrate a statistically significant overall survival benefit as both pre-operative and post-operative treatment compared to chemotherapy alone in high-risk early-stage TNBC.

Industry Experts and Physician Views for Triple Negative Breast Cancer (TNBC)

To keep up with TNBC market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the TNBC emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in TNBC, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts conducted with 8+ KOLs to gather insights at country level. Centers such as the Icahn School of Medicine, Dana-Farber Cancer Institute, University of Tubingen, Institut Gustave Roussy etc. were contacted.

Their opinion helps understand and validate current and emerging TNBC therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in TNBC.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of TNBC, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of TNBC, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the TNBC market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM TNBC market.

Report Insights

• TNBC Patient Population Forecast
• TNBC Therapeutics Market Size
• TNBC Pipeline Analysis
• TNBC Market Size and Trends
• TNBC Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) bottom-up forecasting
• Artificial Intelligence (AI)-enabled market research report
• 11-year forecast
• TNBC Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• TNBC Treatment Addressable Market (TAM)
• TNBC Competitive Landscape
• TNBC Major Companies Insights
• TNBC Price Trends and Analogue Assessment
• TNBC Therapies Drug Adoption/Uptake
• TNBC Therapies Peak Patient Share analysis

Report Assessment

• TNBC Current Treatment Practices
• TNBC Unmet Needs
• TNBC Clinical Development Analysis
• TNBC Emerging Drugs Product Profiles
• TNBC Market Attractiveness
• TNBC Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the TNBC market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of TNBC?
• What are the disease risks, burdens, and unmet needs of TNBC? What will be the growth opportunities across the 7MM concerning the patient population with TNBC?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of TNBC? What are the current guidelines for treating TNBC in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the TNBC market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. TNBC Market Overview at a Glance

• 3.1. Market Share (%) Distribution of TNBC by Therapies in the 7MM in 2025
• 3.2. Market Share (%) Distribution of TNBC by Therapies in the 7MM in 2036

4. Executive Summary

5. Key Events

6. Disease Background and Overview

• 6.1. Introduction
• 6.2. Various Subtypes of Breast Cancer Based on Immunohistochemical Expression
• 6.3. TNBC Overview
  • 6.3.1. Intrinsic Molecular Subtypes in TNBC
  • 6.3.2. Characteristics of Tumor Microenvironment in TNBC
  • 6.3.3. Potential Risk Factors
  • 6.3.4. Clinical Presentation
  • 6.3.5. Characterization of HER2-low Breast Cancers
• 6.4. Diagnosis
  • 6.4.1. Staging
  • 6.4.2. Grading
  • 6.4.3. Clinical Prognostic Stage
  • 6.4.4. Pathological Prognostic Stage
  • 6.4.5. American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
  • 6.4.6. Recommendations for HER2 Testing in Breast Cancer: American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Clinical Practice Guideline Update
  • 6.4.7. Diagnostic Algorithm
• 6.5. Treatment and Management
  • 6.5.1. NCCN Clinical Practice Guidelines in Oncology for Breast Cancer
  • 6.5.2. ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Early Breast Cancer
  • 6.5.3. ESMO Clinical Practice Guideline for the Diagnosis, Staging, and Treatment of Patients with Metastatic Breast Cancer
  • 6.5.4. Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for Breast Cancer - 2022 Update
  • 6.5.5. Treatment Algorithm

7. Epidemiology and Market Forecast Methodology

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: 7MM
  • 8.2.1. Incident Cases of Breast Cancer
  • 8.2.2. Incident Cases of TNBC
  • 8.2.3. Gene Mutation-specific Incident Cases of TNBC
  • 8.2.4. Stage-specific Incident Cases of TNBC
  • 8.2.5. Age-specific Incident Cases of TNBC
• 8.3. Total Incident Cases of Breast Cancer in the 7MM
• 8.4. Total Incident Cases of TNBC in the 7MM
• 8.5. The United States
  • 8.5.1. Total Incident Cases of TNBC in the US
  • 8.5.2. Gene Mutation-specific Incident Cases of TNBC in the US
  • 8.5.3. Stage-specific Incident Cases of TNBC in the US
  • 8.5.4. Age-specific Incident Cases of TNBC in the US
  • 8.5.5. Line-wise Treated Incident Cases of TNBC in the US
• 8.6. EU4 and the UK
  • 8.6.1. Total Incident Cases of TNBC in EU4 and the UK
  • 8.6.2. Gene Mutation-specific Incident Cases of TNBC in EU4 and the UK
  • 8.6.3. Stage-specific Incident Cases of TNBC in EU4 and the UK
  • 8.6.4. Age-specific Incident Cases of TNBC in EU4 and the UK
  • 8.6.5. Line-wise Treated Incident cases of TNBC in EU4 and the UK
• 8.7. Japan
  • 8.7.1. Total Incident Cases of TNBC in Japan
  • 8.7.2. Gene Mutation-specific Incident Cases of TNBC in Japan
  • 8.7.3. Stage-specific Incident Cases of TNBC in Japan
  • 8.7.4. Age-specific Incident Cases of TNBC in Japan
  • 8.7.5. Line-wise Treated Incident Cases of TNBC in Japan

9. Patient Journey

10. Marketed Therapies

• 10.1. Competitive Landscape: Marketed Drugs
• 10.2. Pembrolizumab (KEYTRUDA): Merck
  • 10.2.1. Product Description
  • 10.2.2. Regulatory Milestone
  • 10.2.3. Other Developmental Activities
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
• 10.3. Sacitzumab govitecan-hziy (TRODELVY): Gilead Sciences
  • 10.3.1. Product Description
  • 10.3.2. Regulatory Milestone
  • 10.3.3. Other Developmental Activities
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy
• 10.4. Talazoparib (TALZENNA): Pfizer
  • 10.4.1. Product Description
  • 10.4.2. Regulatory Milestones
  • 10.4.3. Other Developmental Activities
  • 10.4.4. Clinical Trials Information
  • 10.4.5. Safety and Efficacy
• 10.5. Olaparib (LYNPARZA): Astra Zeneca/Merck
  • 10.5.1. Product Description
  • 10.5.2. Regulatory Milestones
  • 10.5.3. Other Developmental Activities
  • 10.5.4. Clinical Trials Information
  • 10.5.5. Safety and Efficacy
• 10.6. Atezolizumab (TECENTRIQ): Roche/Genentech
  • 10.6.1. Product Description
  • 10.6.2. Regulatory Milestones
  • 10.6.3. Other Developmental Activities
  • 10.6.4. Clinical Trials Information
  • 10.6.5. Safety and Efficacy

11. Emerging Drug Profiles

• 11.1. Key Cross Competition of Emerging Drugs
• 11.2. Datopotamab Deruxtecan (DATROWAY): AstraZeneca/Daiichi Sankyo
  • 11.2.1. Drug Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Trials Information
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analysts' View
• 11.3. Adagloxad Simolenin: OBI Pharma
  • 11.3.1. Drug Description
  • 11.3.2. Other Developmental Activities
  • 11.3.3. Clinical Trials Information
  • 11.3.4. Safety and Efficacy
  • 11.3.5. Analysts' View
• 11.4. Enfortumab vedotin (PADCEV): Astellas Pharma/Pfizer
  • 11.4.1. Drug Description
  • 11.4.2. Other Developmental Activities
  • 11.4.3. Clinical Trials Information
  • 11.4.4. Safety and Efficacy
  • 11.4.5. Analysts' View
• 11.5. Tilarginine: Galera Therapeutics
  • 11.5.1. Drug Description
  • 11.5.2. Other Developmental Activities
  • 11.5.3. Clinical Trials Information
  • 11.5.4. Safety and Efficacy
  • 11.5.5. Analysts' View
• 11.6. BNT327/PM8002: BioNTech
  • 11.6.1. Drug Description
  • 11.6.2. Other Developmental Activities
  • 11.6.3. Clinical Trials Information
  • 11.6.4. Safety and Efficacy
  • 11.6.5. Analysts' View
• 11.7. Durvalumab (IMFINZI): AstraZeneca
  • 11.7.1. Drug Description
  • 11.7.2. Other Developmental Activities
  • 11.7.3. Clinical Trials Information
  • 11.7.4. Safety and Efficacy
  • 11.7.5. Analysts' View

12. TNBC: Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Attribute Analysis
• 12.4. Key Market Forecast Assumptions
• 12.5. Total Market Size of TNBC in the 7MM
• 12.6. Market Size of TNBC by Therapies in the 7MM
• 12.7. Market Size of TNBC in the United States
  • 12.7.1. Total Market of TNBC
  • 12.7.2. Market Size of TNBC by Therapies in the United States
• 12.8. Market Size of TNBC in EU4 and the UK
  • 12.8.1. Total Market Size of TNBC
  • 12.8.2. Market Size of TNBC by Therapies in EU4 and the UK
• 12.9. Market Size of TNBC in Japan
  • 12.9.1. Total Market Size of TNBC
  • 12.9.2. Market Size of TNBC by Therapies in Japan

13. Key Opinion Leaders' Views

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

• 16.1. The United States
  • 16.1.1. CMS
• 16.2. In EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. The United Kingdom
• 16.3. Japan
  • 16.3.1. MHLW

17. Appendix

• 17.1. Acronyms and Abbreviations
• 17.2. Bibliography
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight